Impax Laboratories Confirms Patent Suit Relating to Generic Detrol Immediate-Release 1 mg and 2 mg Tablets

Impax Laboratories, Inc. IPXL today confirms that Pfizer Inc. PFE, Pharmacia & Upjohn Company LLC and Pfizer Health AB have filed suit for patent infringement against Impax in the United States District Court for the District of New Jersey in connection with Detrol immediate-release, 1 mg and 2 mg tablets. Impax filed its Abbreviated New Drug Application containing a paragraph IV certification for a generic version of Detrol® with the U.S. Food & Drug Administration. Following receipt of the notice from the FDA that Impax's ANDA had been accepted for filing, Impax notified the New Drug Application holder and patent owner of its paragraph IV certification.